Alexandria Real Estate, Merck Ink Long-Term Pharma Lease

Published 11/30/2016, 10:39 PM
Updated 10/23/2024, 11:45 AM

Alexandria Real Estate Equities, Inc. (NYSE:ARE) has announced its tie up with Merck & Co., Inc. (NYSE:MRK) , the global healthcare company to operate its new West Coast research facility. This move brings a top pharmaceutical company to the dynamic pharma community and strengthens Bay Area’s position as a top center for healthcare collaboration and research.

With this, Merck executed a long-term, full-building lease for a nine-story, 294,000 rentable square feet laboratory/office campus at 213 East Grand Avenue in the heart of the South San Francisco innovation cluster. The construction work for this facility is likely to begin in early 2017 and is anticipated to be placed into service in early 2019.

The state-of-the-art research center being developed by Alexandria will feature open green space to support health and wellness as well as function as space for events. An auditorium, a fitness center and a lively cafe and terrace with waterfront views have been designed to prop up research and innovation.

Currently both Alexandria Real Estate Equities and Merck carry a Zacks Rank #3 (Hold). For the current year, Alexandria Real Estate Equities’ estimates remained unchanged at $5.52 per share. Year to date, the company’s share price surged 21.3%, whereas this rise for the Zacks categorized REIT and Equity Trust – Other industry was 1.6%.

A couple of better-ranked stocks in the REIT space include Seritage Growth Properties (NYSE:SRG) and American Tower Corporation (NYSE:AMT) . Both these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Seritage Growth Properties’ current-year funds from operations (“FFO”) estimates have moved up 0.9% over the past one month to $2.34 per share.
Current-year estimates for American Tower Corporation moved up 0.2% to $5.55 over the past month.

Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



MERCK & CO INC (MRK): Free Stock Analysis Report

AMER TOWER CORP (AMT): Free Stock Analysis Report

ALEXANDRIA REAL (ARE): Free Stock Analysis Report

SERITAGE GROWTH (SRG): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.